In a new editorial published in PLOS NTDs, “The NTDs and Vaccine Diplomacy in Latin America: Opportunities for United States Foreign Policy,” Sabin Vaccine Institute (Sabin) President Dr.

Titled, “New chapter unfolding in the fight against dengue with an unwritten ending,” the Dengue Vaccine Initiative’s (DVI) editorial just published in the October issue of Transactions

Sabin Vaccine Institute Awarded Funding to Advance Therapeutic Vaccine Development for Chagas Disease

WASHINGTON, D.C. — September 16, 2014 — The Sabin Vaccine Institute (Sabin) today announced that its product development partnership (Sabin PDP) received $2 million from the Global Health Innovative Technology Fund (GHIT Fund) to develop a new therapeutic vaccine formulation for Chagas disease. Baylor College of Medicine, Eisai Co., Ltd. (Eisai) and Aeras are partnering on this project with the Sabin PDP, based at the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development in Houston, Texas.

Pages

Subscribe to RSS - Research & Development